Related Experiment Videos
Anti-TNF agents in Crohn's disease
1Department of Internal Medicine, University Hospital Gasthuisberg, B-3000 Leuven, Belgium.
Expert Opinion on Investigational Drugs
|November 4, 2000
Summary
Anti-tumor necrosis factor (TNF) therapies, like infliximab, offer effective treatment for Crohn's disease, overcoming limitations of corticosteroids. Further research is needed to optimize long-term use and safety of these biological agents.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Current Crohn's disease treatments, primarily corticosteroids, have limited long-term efficacy and significant side effects.
- Biological therapies targeting immune responses present novel management strategies for chronic inflammatory conditions.
- Tumor necrosis factor (TNF) is a key cytokine in Crohn's disease pathogenesis, making anti-TNF agents a focus for treatment development.
Purpose of the Study:
- To review the efficacy and safety of anti-TNF agents, particularly infliximab, in managing Crohn's disease.
- To highlight infliximab's role as a therapeutic breakthrough for refractory Crohn's disease.
- To discuss the need for further research on long-term anti-TNF antibody use, safety monitoring, and alternative agents.
Main Methods:
- Review of clinical trial data for monoclonal anti-human TNF antibodies.
- Analysis of efficacy and tolerability of infliximab in acute Crohn's disease.
- Examination of concerns regarding immunogenicity (HACA) and potential side effects.
Main Results:
- Infliximab (a chimeric anti-TNF IgG1 antibody) has demonstrated effectiveness and good tolerability in managing acute Crohn's disease.
- Infliximab has received regulatory approval (FDA and EMMA) for Crohn's disease treatment.
- Despite concerns about human antichimeric antibodies (HACA) and lymphoproliferative disorders, infliximab offers significant clinical benefit for refractory cases.
Conclusions:
- Anti-TNF antibodies, exemplified by infliximab, represent a major therapeutic advance for Crohn's disease.
- Further studies are essential to determine optimal dosing, long-term safety, and efficacy for maintaining remission.
- Evaluation of alternative anti-TNF strategies, including etanercept and thalidomide, is warranted.